Antiviral Resistance Mutations and Genotype-Associated Amino Acid Substitutions in Treatment-Naïve Hepatitis B Virus-Infected Individuals from the Indian Subcontinent

A.M. Ismail a P. Samuel b C.E. Eapen c R. Kannangai a P. Abraham a
Departments of aClinical Virology, bBiostatistics and cGastrointestinal Sciences, Christian Medical College, Vellore, India

Key Words
Antiviral therapy · Mutation · Drug resistance · Genotypes · Hepatitis B virus · Reverse transcriptase

Abstract
Background/Aims: Antiviral resistance is a major challenge to the treatment currently available for hepatitis B virus (HBV). In this study, mutations that may affect the antiviral efficacy in treatment-naïve HBV-infected individuals were analyzed. Methods: Ninety-seven treatment-naïve HBV-infected individuals were included in this study. HBV reverse transcriptase (rt) domains were sequenced and nucleotide differences were compared to GenBank wild-type sequences. Furthermore, HBV genotypes, subgenotypes and subtypes were determined by analyzing surface gene sequences. Results: An adefovir-related rtI233V mutation was identified in 4 subjects. The rtS213T lamivudine and entecavir refractory mutant was presented in 3 individuals. Altogether, drug-related, atypical and novel HBVrt amino acid substitutions were seen in 73 positions. The HBV genotypes A, C, D and G were depicted in 15, 21, 60 and 1 individuals, respectively. There were 17 HBVrt amino acid substitutions that are associated with certain genotypes of HBV. Mutations in HBVrt corresponded to established surface gene mutations in 9 patients. Conclusion: This data shows that antiviral-resistant HBV strains do exist in treatment-naïve individuals in this region. Further studies are essential to characterize the role of HBVrt amino acid substitutions in response to anti-HBV therapy.

Introduction
The goal of antiviral treatment is to achieve viral suppression. However, the virus evolves strategies to overcome the drug selection pressure, thereby escaping the antiviral action. Antiviral resistance is a major concern for the therapeutic management of hepatitis B virus (HBV) infection. The incidence of lamivudine resistance at the end of 24 months in hepatitis B e antigen (HBeAg)-positive and -negative patients was 39.5 and 25.9%. Likewise, for telbivudine it is 25.1 and 10.8%, respectively [1]. The cumulative probability of adefovir and entecavir resistance for the same duration was found to be 3 and 0.5% [2, 3].

With 50 million carriers, India has the second largest population of individuals with chronic HBV infection worldwide [4]. Locarnini and Mason [5] have described HBV drug resistance as the single most significant factor in treatment failure of HBV. All the available nucleoside/nucleotide analogues for HBV target the reverse transcriptase (rt) domain of polymerase gene, and mutations
occurring in the conserved domains of HBVrt have been shown to confer resistance to antiviral drugs [6, 7]. Furthermore, HBVrt lacks the proofreading activity and constantly evolves with substitution rates of $4.2 \times 10^{-5}$ nucleotide substitutions/site/year [8, 9]. Consequently, viral mutants are generated during the course of disease, leading to the development of viral quasispecies [5]. The presence of pre-existing antiviral-resistant mutants and the mutation patterns that accumulate over time may affect the efficacy of subsequent treatments.

The typical mutations considered as primary mutations to lamivudine involve rtM204V/I, and for adefovir it is rtA181V/T and rtN236T [10, 11]. Other amino acid substitutions at sites rtL80I, rtI169T, rtV173L, rtL180M, rtA181T/S and rtQ215S occur during lamivudine therapy to restore the replication capability, and are called secondary/compensatory mutations [12]. Likewise, entecavir-related mutations require combinations of substitutions at positions rtI169T, rtL180M, rtT184G, rtS202I, rtM204V and rtM250V [13, 14]. The frequency of rtM204I/V mutations in lamivudine-experienced Indian patients was found to be 29% at 18 months [15].

Eight HBV genotypes (A–H) and subgenotypes within certain HBV genotypes have been identified [16]. The HBV strains are also distinguished into hepatitis B surface antigen (HBsAg) subtypes and there is a correlation between subtypes and genotypes [17]. Recently, genotype-dependent polymorphic amino acid positions in HBVrt region were identified, illustrating different genomic variability among HBV genotypes that may influence the development of drug resistance mutants [18].

Recent reports showing the existence of antiviral resistance strains in treatment-naïve hepatitis B individuals alert the need for baseline monitoring of antiviral resistance mutants [19–21]. Hence in the present study we attempted to identify and analyze the HBVrt amino acid substitutions capable of conferring resistance to antivirals in treatment-naïve HBV-infected individuals from the Indian subcontinent. In addition, the effect of HBVrt amino acid substitutions on the overlapping surface (S) gene was also studied.

Materials and Methods

Subjects

Blood samples obtained from 97 HBV-infected individuals attending the liver clinic of a tertiary care teaching hospital in South India who were HBV DNA-positive were included in this study by convenient sampling. Subjects were recruited between April 2007 and August 2009 and were referred to the Department of Clinical Virology for HBV quantification. Plasma was separated on the same day of blood collection and was stored in aliquots at –60°C until further analysis. All subjects were HBsAg-positive, hepatitis C virus (HCV) antibody (Ab)-negative, human immunodeficiency virus (HIV)-negative and treatment-naïve. The study was approved by the institutional review board and informed written consent was obtained from all the subjects. Clinical details and serum alanine transaminase levels (ALT) were obtained from the patient’s hospital records.

Serology Markers

HBsAg and HBeAg testing were performed in EIA (DiaSorin S.P.A., Saluggia, Italy). HCV Ab and HIV were screened in Ortho HCV 3.0 (Ortho Clinical Diagnostics, Raritan, N.J., USA) and AxSYM HIV Ag/Ab combo (Abbott, Wiesbaden, Germany).

DNA Isolation

DNA was extracted from 200 μl of blood plasma using the QIAamp DNA Blood MiniKit (Qiagen GmbH, Hilden, Germany) as per the manufacturer’s instructions. Finally, the extract was resuspended in 50 μl of elution buffer.

HBV DNA Quantification

HBV DNA was quantified using artus® HBV RG PCR (Qiagen GmbH, Hilden, Germany) in the Rotor-Gene 3000 or 6000 platform (Corbett Research, Mortlake, Vic., Australia).

HBV Polymerase/rt Gene PCR

HBV polymerase gene covering the entire rt region was amplified (1,323 bp) using high-fidelity platinum Taq DNA polymerase (Invitrogen, Carlsbad, Calif., USA) with a HBV DNA template of 5 in 50 μl reaction volume. The primer sequences and PCR cycling conditions used have been described previously [13].

DNA Purification and Sequencing Analysis

The amplified PCR products were purified by Multiscreen® PCR plate (Millipore, Billerica, Mass., USA). Sequencing reaction was carried out with two sets of primer sequences, SP1- CTC CAG TTT AGG AAC AGT AAA CCC, ISP2- CGA ACC ACT GAA AAA ATG GC, HBVF5S- TGT ATT CCC ATC CCA TC, HBV4- GCT AGG AGT TCC GCA GTA TGG A [13, 22], and the ABI Prism Big Dye terminator cycle sequencing reaction kit. Briefly, 1 μl of the purified PCR product is mixed with 1.6 pmoles of the primer, and 1 μl of the reaction mix with 2 μl of the sequencing buffer, making the volume to 10 μl with nuclease-free water. The cycling conditions consisted of 25 cycles of 96°C for 15 s, 50°C for 20 s and 60°C for 4 min. Excess salts and dye terminators were removed from the sequencing mixture using Montage SEQ96 filtration (Millipore). The sequencing reactions were run on an ABI PRISM 310 genetic analyzer (PE Applied Biosystems, Foster City, Calif., USA). Obtained bidirectional sequences were analyzed using BioEdit v7.0.9 and multiple sequence alignment was performed using the built-in CLUSTALW integrated in MEGA4 [23]. Nucleotide substitutions were revealed by comparing the study sequences with the consensus sequence of the 600 HBV GenBank sequence (accession numbers in suppl. material www.karger.com/doi/10.1159/000323521). The consensus was generated aligning 3 different datasets. An amino acid differences table was generated and analyzed by CUBIT GUI.
Ismail /Samuel /Eapen /Kannangai /Abraham  
Intervirology 2012;55:36–44

These sequences were also analyzed for in vitro phenotypic prediction of HBV drug resistance mutations using the Genafor/Arevir-geno-2pheno (hbv) drug resistance tool (Genafor, Bonn, Germany; http://hbv.bioinf.mpi-inf.mpg.de/index.php).

Nucleotide sequences generated from this study are deposited in GenBank database under accession numbers GU798963 to GU799059.

HBV Surface Gene Analysis

HBV S gene sequences were similarly analyzed to identify the overlapping mutations. HBV genotypes and subgenotypes were determined by aligning study sequences with published sequences representing all HBV genotypes and subgenotypes [16, 24, 25]. Phylogenetic analysis was performed in MEGA4 using the neighbor-joining method with a bootstrap test of 1,000 replicates and maximum composite likelihood algorithm. HBsAg subtypes were predicted by S gene amino acid codons 122, 160, 127, 159 and 140 as described elsewhere [17].

Statistical Analysis

The number of HBVrt amino acid substitutions and HBV DNA level between the genotypes were compared using a Kruskal-Wallis test. A p value of $<0.05$ was considered statistically significant. Correlations between the HBV DNA level and ALT, rt amino acid substitution and age were analyzed using Spearman’s correlation coefficient. The median HBV DNA and median number of rt amino acid substitution was compared between HBeAg status using a Mann-Whitney U test. All analysis was done using STATA 11 (StataCorp, College Station, Tex., USA).

Results

In 97 subjects, 80 (83%) were male and the median age was 35 years (4–75 years). Sixty-three (65%) were HBeAg-positive and there was a significant association between HBeAg status and median HBV DNA level ($4 \times 10^5$ IU/ml; $p < 0.001$), range 219–9 $\times 10^8$ IU/ml. The median ALT was 40 U/l (12–624 U/l) and there was a correlation between ALT and viral load ($r = 0.26, p = 0.008$). Twenty-six (27%) individuals had a family history of HBV infection and 13 (13%) had undergone surgical or dental procedures.

Comparison with HBV GenBank sequences revealed rt amino acid substitutions in 73 amino acid sites (table 1). An adefovir-related rtI233V mutation was seen in 4 patients. An antiviral-resistant mutant (rtS213T) that restores the replication fitness in lamivudine- and entecavir-experienced patients was seen in 3 patients. Likewise, rtI91L, rtS213T and rtN238S compensatory mutations were identified individually. Atypical mutations with new amino acid substitutions in positions rtV84, rtT128, rtS213, rtV214, rtQ215, rtS219, rtP237, rtN238 and rtY245 were seen in 19 individuals. Altogether, functional domain mutations in HBVrt domains F, A, D and E were seen in 2, 5, 9 and 2 individuals, respectively. One subject had a single mutation in both the A and D domains. Additionally, novel amino acid substitutions were seen in 62 amino acid positions of the HBVrt region.

rtI91L and rtL217R naturally occurring polymorphisms

### Table 1. HBVrt amino acid substitutions observed in this study

<table>
<thead>
<tr>
<th>rtA/P/S/T7D</th>
<th>rtR100G</th>
<th>rtK149R/Q</th>
<th>rtY245C/H</th>
<th>rtM309K/I</th>
</tr>
</thead>
<tbody>
<tr>
<td>rtH9Y</td>
<td>rtL115V</td>
<td>rtF151Y</td>
<td>rtS246H</td>
<td>rtA313S</td>
</tr>
<tr>
<td>rtI14L</td>
<td>rtN121S</td>
<td>rtR153Q/W</td>
<td>rtG255D</td>
<td>rtC314S</td>
</tr>
<tr>
<td>rtI16T</td>
<td>rtF/I/L/V122H/N</td>
<td>rtI187L</td>
<td>rtW257Y</td>
<td>rtQ346H</td>
</tr>
<tr>
<td>rtA21S</td>
<td>rtN123D</td>
<td>rtS213T*/N</td>
<td>rtT259S</td>
<td>rtQ319R</td>
</tr>
<tr>
<td>rtV23I</td>
<td>rtQ125K</td>
<td>rtV214A*/E</td>
<td>rtD/E263S</td>
<td>rtT322S</td>
</tr>
<tr>
<td>rtA/S/T38K/E</td>
<td>rtH126Y/R</td>
<td>rtQ215S*/H/P</td>
<td>rtI/L/V266R/K</td>
<td>rtP325L</td>
</tr>
<tr>
<td>rtI/N/S/T53Y/D</td>
<td>rtT128N*/L</td>
<td>rtL217R</td>
<td>rtH/Q267L</td>
<td>rtT326A</td>
</tr>
<tr>
<td>rtA/P/S/T54Y/H</td>
<td>rtM129V/L</td>
<td>rtE218N</td>
<td>rtH/Q271K</td>
<td>rtY327F</td>
</tr>
<tr>
<td>rtN76S/D</td>
<td>rtQ130P</td>
<td>rtS219T*/A</td>
<td>rtV278I/T/L</td>
<td>rtA329T/V</td>
</tr>
<tr>
<td>rtS78T/Y</td>
<td>rtI132M</td>
<td>rtT225S</td>
<td>rtN729D</td>
<td>rtC332S/R/Y</td>
</tr>
<tr>
<td>rtV84I</td>
<td>rtD/E134N</td>
<td>rtI233V*</td>
<td>rtI290L</td>
<td>rtK333A/N/Q</td>
</tr>
<tr>
<td>rtI91L</td>
<td>rtS135N/Y</td>
<td>rtP237T</td>
<td>rtV291T</td>
<td>rtN337H</td>
</tr>
<tr>
<td>rtV103I</td>
<td>rtR138K</td>
<td>rtK241Q</td>
<td>rtL293I</td>
<td></td>
</tr>
<tr>
<td>rtS106C</td>
<td>rtV142E</td>
<td></td>
<td>rtY305F</td>
<td></td>
</tr>
</tbody>
</table>

On comparison with HBV GenBank consensus sequence, amino acid substitutions in 73 positions were seen. Shaded positions include rt-conserved domain substitutions and * indicates amino acid substitutions that are crucial for antiviral resistance to HBV.
that respond poorly to lamivudine and adefovir were seen in 75 and 3 individuals, respectively [26, 27]. On statistical analysis, there was a significant association between age and number of rt amino acid substitutions (r = 0.39, p < 0.0001) and a significant difference between median number of rt amino acid substitution and HBeAg status (p = 0.01). All the study sequences when analyzed for the phenotypic prediction of drug resistance in geno2pheno (hbv) database showed adefovir resistance in 4 individuals carrying the rtI233V mutation.

On analyzing the S gene, HBV genotype D was seen most commonly (n = 60) with the subgenotype/subtype split of D1/ayw2 (n = 6), D2/ayw2 (n = 3), D2/ayw3 (n = 45), D3/ayw2 (n = 3), D4/ayw2 (n = 1) and D5/ayw3 (n = 2). The HBV subgenotype/subtype A1/adw2 and C1/adr was seen in 15 and 21 individuals. One subject was infected with HBV genotype G/ayw1 (fig. 1 and 2). Sequence analyses also showed some HBVrt amino acid substitutions that are common and specific to certain genotypes. In the present study, rtA/P/S/T54H/Y (100%),
rtS135Y/N (78%), rtK149Q (83%), rtW257Y (88%), rtT259S (98%) and rtI/L/V266R/K (18%) were only seen in HBV genotype D. Specifically, rtI/N/S/T53D and rtH126R was observed in subgenotypes D2 with a frequency of 83 and 87% respectively. Likewise, rtF151Y and rtR153W/Q was specific to all study samples of HBV genotype A, while rtF/I/L/V122N and rtC332S were seen in 53 and 87% of this genotype, respectively. In HBV genotype C populations, rtH9Y (100%) is the only substitution that was specific to this genotype. In addition, some of the rt amino acid substitutions are specific to certain genotypes and are shown in Table 2.

There was a significant difference between HBV genotypes and the mean number of HBVrt amino acid substitutions between the A and C genotypes, and between the C and D genotypes (p < 0.0001, respectively), but no significant difference was found between genotypes A and D. However, 5 (12%) of the genotype D subjects had >10 amino acid substitution (Table 3). The difference in HBV DNA load and genotype was not statistically significant.

On comparison of overlapping S gene sequences with reference sequences, amino acid substitutions were seen in 57 amino acid positions. The rtR153Q substitution corresponded to the sG145R vaccine escape mutant in 1 patient infected with HBV genotype G, and amino acid substitution sP120T corresponding to rtT128N was seen in another patient. Likewise, neutralizing antibody escape mutants sI/N/T126S and sK141E were detected in 2 and 1 patients, respectively. The rtS78T substitution re-
sulted in a sC69 stop codon mutation in 3 patients. Overall, HBVrt amino acid substitutions resulted in ‘S’ gene amino acid changes in 11 positions (fig. 3).

Discussion

In this study, we have described HBVrt amino acid substitutions from 97 HBV-infected subjects who have not experienced antiviral drugs to HBV. As is widely reported, the HBeAg positivity and raised ALT levels correlated with higher HBV DNA loads in these individuals. We attempted to identify novel amino acid substitutions by comparing the study sequences with maximum wild-type sequences from GenBank. This allowed us to identify some unique mutations that are drug-related, atypical amino acid substitutions in positions of known antiviral resistant target sites [20] and some novel amino acid substitutions not yet reported in the literature. There was a significant positive relationship between the age of HBV-infected individuals and the number of rt amino acid substitutions. As discussed by Solmone et al. [28], this may be due to the accumulation of substitutions in older age groups.

Previously, this laboratory has reported prevailing circulation of HBV genotype D followed by A and C from chronic hepatitis B groups [29, 30]. The present study also shows a preponderance of genotype D, but the frequency of genotype C (22%) exceeded that of genotype A (15%). This may be due to the inclusion of more subjects from eastern India (42/97, 43%) where genotype C is common [31, 32]. In our study, subgenotype D1, D2, D3 and D5 were seen with a frequency of 10, 80, 5 and 3.3%, respectively, which is comparable to an earlier report [33]. One patient from Bhutan was infected with HBV subgenotype D4 and had a unique rtE/D263S and rtA329V substitution. Banerjee et al. [34] and Kumar et al. [35] reported a sT125M mutation in the ‘a’ determinant region of the S gene to be associated with the ayw3 subtype of genotype D. A similar finding was obtained in the ayw3 subtype of D2 (16%) and D5 (100%) subgenotype in our study subjects. It has been reported by Norder et al. [16] that this mutant is associated with intravenous drug use. However, family history of jaundice and surgical procedures were the only risk factors of HBV infection in our study subjects. One patient carried HBV genotype G, which has been previously reported from countries like France, Germany, USA, Mexico and more recently from an Indian patient with occult HBV [35]. Intriguingly, there was no history of travel or receipt of imported blood products in this individual. The presence of HBV genotype G in our study population alerts us that larger studies may reveal genotypes from geographically distant regions.

In samples analyzed, no known ‘hot-spot’ mutations that can independently affect the antiviral susceptibility were seen. The rtI233V mutation common in HBV genotype D, which can affect the antiviral efficacy to adefovir, was seen in 4 subjects: 3 (5%) HBV genotype D and 1 (4.76%) genotype C, respectively [36]. In analyzing our study sequences, this is the only HBVrt mutation that

<table>
<thead>
<tr>
<th>Domain</th>
<th>Amino Acid</th>
<th>Protein Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>I (G)</td>
<td>rtS78T</td>
<td>sC69stop</td>
</tr>
<tr>
<td>II (F)</td>
<td>rtA/S/T38K/E</td>
<td>sQ30K</td>
</tr>
<tr>
<td></td>
<td>rtV84I</td>
<td>sM75I</td>
</tr>
<tr>
<td></td>
<td>rtT128N/L</td>
<td>sP120T/S</td>
</tr>
<tr>
<td></td>
<td>rtR138K</td>
<td>sG130N/S</td>
</tr>
<tr>
<td></td>
<td>rtV142E</td>
<td>sF/S134H/N</td>
</tr>
<tr>
<td></td>
<td>rtR153Q</td>
<td>sG145R</td>
</tr>
<tr>
<td>C</td>
<td>rtS213T/N</td>
<td>sS204R/K</td>
</tr>
<tr>
<td></td>
<td>rtV214A</td>
<td>sL205M</td>
</tr>
<tr>
<td></td>
<td>rtQ215H</td>
<td>sY206F</td>
</tr>
<tr>
<td></td>
<td>rtI16T</td>
<td>sF8I</td>
</tr>
<tr>
<td></td>
<td>rtA/S/T38K/E</td>
<td>sQ30K</td>
</tr>
<tr>
<td></td>
<td>rtV84I</td>
<td>sM75I</td>
</tr>
<tr>
<td></td>
<td>rtT128N/L</td>
<td>sP120T/S</td>
</tr>
<tr>
<td></td>
<td>rtR138K</td>
<td>sG130N/S</td>
</tr>
<tr>
<td></td>
<td>rtV142E</td>
<td>sF/S134H/N</td>
</tr>
<tr>
<td></td>
<td>rtR153Q</td>
<td>sG145R</td>
</tr>
<tr>
<td></td>
<td>rtS213T/N</td>
<td>sS204R/K</td>
</tr>
<tr>
<td></td>
<td>rtV214A</td>
<td>sL205M</td>
</tr>
<tr>
<td></td>
<td>rtQ215H</td>
<td>sY206F</td>
</tr>
</tbody>
</table>

Fig. 3. HBVrt amino acid substitutions conferring overlap surface gene mutations. HBVrt domains (A–G) and respective amino acid (aa) positions are shown [45]. ‘n’ indicates number of patients. One patient (*) presented with substitution in positions rt38 (s30) and rt153 (s145), another patient (**) had rt38 (s30) and rt215 (s206) substitutions and one patient (†) carried rt213 (s204) and rt214 (s205) amino acid substitutions.
showed a resistance profile to adefovir in the geno2pheno (hbv) drug resistance tool. Recently, Schildgen et al. [37] showed adefovir failure due to the pre-existing rtI233V mutation. However, the role of the rtI233V mutation and adefovir response remains contradictory [10, 38, 39].

Structural biology studies have shown that HBVrt C–D interdomain mutations at rt215 and rt219 can alter the nucleotide triphosphate binding active site [7, 12]. Amino acid substitutions in each of these positions were identified in 5 individuals. Likewise, the rtS213T mutation that re-establishes the replication fitness to lamivudine and entecavir therapy was seen in 3 individuals. Amino acid substitutions at rt214, rt237 and rt238 that lie in close proximity to lamivudine-, adefovir- and entecavir-related key signature mutations were also seen. In addition to these HBVrt interdomain substitutions, functional mutations in the conserved domains A–E were seen in 17 subjects. HBVrt shares a good sequence homology in the catalytic regions of HIV domains A–G [7]. Unlike HIV, there have been no reports of domain F antiviral-related mutations for HBV [40]. In our study, rtA/S/T38K in the F domain was seen in 2 subjects and the role of this substitution needs to be established. Likewise, predominant substitution of rtW257Y and rtN248H in E domain is noteworthy.

Comparison to the GenBank consensus sequence allowed us to identify some unique amino acid substitutions that are genotype-specific and some substitutions that are common across certain subgenotypes/subtypes. Identification of more specific genotypic markers will aid in framing an algorithm for genotype/subgenotype classifications just like specifying HBsAg subtypes. This will also pave the way to identify markers that are predictors of response and nonresponse to HBV drugs. A2 subgenotypes containing L217R polymorphisms are shown to respond poorly in adefovir-treated individuals. This polymorphism was seen in 2 of our D2 subgenotypes and 1 C1 subgenotypes. The rtI91L naturally occurring polymorphism is predominantly seen in lamivudine-failure patients. This polymorphism was found in HBV genotype C, D and G in our study subjects and all genotype A patients in this study had rtI91L. Better characterization of naturally occurring polymorphisms and drug-related resistance mutations are required for pointing out genotypic markers of response and nonresponse. All individuals carried at least 1 amino acid substitution when compared to the previously reported GenBank sequences. Statistical analysis of the number of HBVrt mutations in relation to HBV genotypes showed a significant difference between genotypes A and C and between C and D. HBV genotype D showed a larger number of substitutions (10–14 substitutions) in 5 individuals. This can potentially have clinical significance in India due to the high burden of chronically infected individuals, extensive usage of antiviral drugs and predominance of genotype D.

The surface gene of HBV is entirely overlapped by the HBVrt region, so mutations occurring in one region may affect the protein coding sequences of the other. HBVrt substitutions resulted in HBV S codon changes in 12 positions. The sG145R vaccine escape mutant and sP120T mutant seen in our study subjects have been shown to partially restore the replication of lamivudine resistant strains in vitro [41]. As reported, these vaccine escape mutants and truncated proteins may have an important effect on immune recognition and diagnostic testing [42]. Some naturally occurring baseline S gene mutations previously reported in Indian patients with virological breakthrough was not seen in our patients, except the sa128V mutation that was seen in 40% of the individuals [43].

This is the first report from the Indian subcontinent to characterize the HBVrt sequence from treatment-naïve individuals. Our findings expand the results of earlier published studies on antiviral-resistant mutants to HBV and overlap S gene mutants. According to present knowledge, the incidence of antiviral resistance is comparatively higher in HBeAg-positive individuals. In our study, HBeAg-negative variants had a higher number of rt amino acid substitutions compared to the HBeAg-positive group. It is reasoned that higher number of rt amino acid changes in the active domain may affect the enzyme activity reducing the replication efficacy of the virus and contribute to treatment response [44]. Follow-up of these individuals is essential to identify if a greater number of rt amino acid substitutions in HBeAg-negative patients can reduce the risk of treatment failure.

Lamivudine is the first orally available drug for HBV and adefovir remains an alternative drug of choice from 2002. As observed in this study, the chance for the presence of pre-existing HBV variants resistant to these drugs is higher when compared to the more newly introduced drugs like entecavir, telbivudine and tenofovir. Hence, to better understand the significance of the observed amino acid substitutions, structural biology studies or phenotypic testing and follow-up of these patients is required.

In summary, we have identified HBVrt amino acid substitutions in treatment-naïve individuals that could reduce the efficacy of currently used antivirals like lamivudine, adefovir and entecavir. Though no established
mutations against any of these drugs was seen in these 97
subjects, the presence of compensatory/secondary mu-
tations that usually occur in treatment-experienced indi-
viduals alerts that the chance of development of ‘hot-spot’
primary mutations in these treatment-naive individuals
is higher. There were 17 HBVrt positions that showed
genotype-specific amino acid substitutions. Future stud-
ies are warranted to identify mutations that would defi-
nitely impact on antiviral efficacy, to explore the role of
atypical and novel amino acid substitutions, and to deter-
mine baseline genotype-specific markers of HBV drug
resistance. Baseline characterization of HBVrt sequences
will have a promising role in therapeutic management of
HBV as all of the currently available oral drugs target this
region.

Acknowledgements

This work was partly funded by an ICMR grant (No. 5/8/7/
7/2008-ECD-I).

References

1 Liaw YF, Gane E, Leung N, Zeuzem S, Wang
Y, Lai CL, Heathcote EJ, Manns M, Bzowej N,
Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong
MJ, Papatheodoridis G, Chen Y, Brown NA,
Albanis E, Galil K, Naoumou NV: 2-year
globe trial results: telbivudine is superior to
lamivudine in patients with chronic hepatici-

2 Tenney DJ, Rose RE, Baldick CJ, Pokornows-
ki KA, Eggers BJ, Fang J, Wicherowski MJ, Xu
D, Yang J, Wilber RB, Colombo RJ: Long-
term monitoring shows hepatitis B virus re-
sistance to entecavir in nucleoside-naive pa-
tients is rare through 5 years of therapy. Hep-

3 Hadzijannij S, Tassopoulos NC, Heathcote
EJ, Chang TT, Kitis G, Rizzetto M, Marcellin
P, Lim SG, Goodman Z, Ma J, Brosgart CL,
Borotto-Esoda K, Arterburn S, Chuck SL:
Long-term therapy with adefovir dipivoxil for
HBsAg-negative chronic hepatitis B for up to
5 years. Gastroenterology 2006; 131:
1743–1751.

4 Prevention of Hepatitis B in India – An
Overview. New Delhi, World Health Orga-
nisation South-East Asia Regional Office,
2002.

5 Locarnini S, Mason WS: Cellular and viro-
logical mechanisms of HBV drug resistance.

6 Stuyver LJ, Locarnini SA, Lok A, Richman
DD, Carman WF, Dienstag JL, Schinazi RF:
Nomenclature for antiviral-resistant human
hepatitis B virus mutations in the poly-

7 Bartholomeusz A, Tehan BG, Chalmers DK:
Comparisons of the HBV and HIV poly-
merase, and antiviral resistance mutations.

8 Nowak MA, Holmes EC: A revised evolution-
ary history of hepatitis B virus (HBV). J Mol

9 Fares MA, Holmes EC: A revised evolution-
ary history of hepatitis B virus (HBV). J Mol

10 Borrotto-Esoda K, Miller MD, Arterburn S:
Pooled analysis of amino acid changes in the
HBV polymerase in patients from four major
adefovir dipivoxil clinical trials. J Hepatol

11 Allen MI, Deslauriers M, Andrews CW, Tip-
tles GA, Walters KA, Tyrrell DL, Brown N,
Condraey LD: Identification and character-
ization of mutations in hepatitis B virus re-
sistant to lamivudine. Lamivudine Clinical
Investigation Group. Hepatology 1998; 27:
1670–1677.

12 Bartholomeusz A, Locarnini SA: Antiviral
drug resistance: clinical consequences and
molecular aspects. Semin Liver Dis 2006; 26:
162–170.

13 Tenney DJ, Levine SM, Rose RE, Walsh AW,
Weinheimer SP, Discotto L, Plym M, Pokor-
nowski K, Yu CF, Angus P, Ayres A, Bar-
tholomeusz A, Sievert W, Thompson G,
Warner N, Locarnini S, Colombo RJ: Clinical
emergence of entecavir-resistant hepatitis B
virus requires additional substitutions in vi-
rus already resistant to lamivudine. Antimi-

14 Colombo RJ, Rose B, Baldick CJ, Levine S,
Pokornowski K, Yu CF, Walsh A, Fang J, Hsu
M, Mazzucco C, Eggers B, Zhang S, Plym M,
Kleszewski K, Tenney DJ: Entecavir resis-
tance is rare in nucleoside-naive patients with

15 Wakil SM, Kazim SN, Khan LA, Raisuddin
S, Parvez MK, Hattab A, Thakur V, Has-
tain SE, Sarin SK: Prevalence and profile of
mutations associated with lamivudine ther-
apy in Indian patients with chronic hepatitis
B in the surface and polymerase genes of
318.

16 Norder H, Courouce AM, Coursaget P, Eche-
varria JM, Lee SD, Mushahwar IK, Robert-
son BH, Locarnini S, Magnus LO: Genetic
diversity of hepatitis B virus strains derived
worldwide: genotypes, subgenotypes, and
HBsAg subtypes. Intervirology 2004; 47:
289–309.

17 Purdy MA, Talegar G, Swenson P, Araujo A,
Fields H: A new algorithm for deduction of
hepatitis B surface antigen subtype determi-
nants from the amino acid sequence. Intervi-
rology 2007; 50:45–51.

18 Liu BM, Li T, Xu J, Li XG, Dong JP, Yang
Y, Yang JX, Yan L, Gao ZY, Li WP, Sun XW,
Wang YH, Xiao J, Hou CS, Zhuang H: Character-
ization of potential antiviral resistance
mutations in hepatitis B virus reverse transcrip-
tase sequences in treatment-naive Chinese
patients. Antiviral Res 2010; 85:512–519.

19 Han Y, Huang LH, Liu CM, Yang S, Li J,
Lin ZM, Kong XF, Yu de M, Zhan DH, Jin GD,
Lu ZM, Gong QM, Zhang XX: Characterisation
of hepatitis B virus reverse transcriptase
sequences in Chinese treatment-naive pa-
tients. J Gastroenterol Hepatol 2009;24:
1417–1423.

20 Sayan M, Akhan SC, Meric M: Naturally oc-
curring amino-acid substitutions to nucleo-
tide analogues in treatment naïve patients

21 Pastor R, Habersetzer F, Fafi-Kremer S, Dof-
foel M, Baumert TF, Gut JP, Stoll-Keller F,
Schwoerer E: Hepatitis virus mutations po-
tentially conferring adefovir/tenofovir resis-
tance in treatment-naive patients. World J

22 Zhang D, Chen J, Deng L, Mao Q, Zheng J,
Wu J, Zeng C, Li Y: Evolutionary selection
associated with the multi-function of over-
lapping genes in the hepatitis B virus. Infect

23 Tamura K, Dudley J, Nei M, Kumar S: Mega:
Molecular evolutionary genetics analysis
(MEGA) software version 4.0. Mol Biol Evol
2007; 24:1596–1599.

24 Lazarević I, Cucic M, Delic D, Svirilh N,
Simonovic J, Jovanovic T: Distribution of
HBV genotypes, subgenotypes and HBsAg
subtypes among chronically infected pa-
2025.


